What you need to know

Prime Therapeutics (Prime) has received a government subpoena as part of a broader pharmacy benefit manager (PBM)-industry-wide investigation related to opioids. The request includes providing a range of documents and data, and Prime is complying with the inquiry while maintaining our commitment to confidentiality and compliance.

For awareness only. No action is required from clients at this time.

Overview

Prime will provide documents in response to the subpoena, which may include materials that contain confidential information about Prime and its clients. The following types of documents and data from 1998-2024 may be produced:

•             Past and current PBM agreements

•             Deidentified claims data for opioids

•             Rebate data for opioids

•             Formularies for all lines of business

•             Emails regarding opioids

Next steps

Prime is deeply committed to protecting the confidentiality of client information. In responding to the subpoena, Prime will take all reasonable steps to designate such information as highly confidential and limit any further disclosure.

Questions

Please email NoticeInquiries@PrimeTherapeutics.com.